Publications
- Comments on the Clinical Development of Ipilimumab2013 | Publication without faculty affiliation
- Long-term therapeutic response after encorafenib and binimetinib therapy - case report2023 | First Faculty of Medicine
- Effect of immunotherapy and radiotherapy in the treatment of Merkel cell carcinoma in a patient with myelodysplastic syndrome2023 | First Faculty of Medicine
- Současné postavení monoterapie anti-PD-1 protilátkami v léčbě pokročilého melanomu2023 | First Faculty of Medicine
- Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial2023 | First Faculty of Medicine
- Imunoterapie a molekulárně cílená léčba u maligního melanomu2022 | First Faculty of Medicine
- Možnosti využití nivolumabu v imunoterapii melanomu2022 | First Faculty of Medicine
- The Abscopal Effect in the Era of Checkpoint Inhibitors2021 | First Faculty of Medicine
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)2021 | First Faculty of Medicine
- Nemelanomové kožní nádory - cemiplimab v léčbě pokročilého a metastazujícího kožního skvamózního karcinomu2021 | First Faculty of Medicine
Loading network view...